Stockchase InsightsIDEXX LaboratoriesIDXXBUY ON WEAKNESSAug 11, 2025

IDXX recently reported solid numbers as its topline growth accelerated to around 15% compared to previous quarters of around mid-to-high single digits. The company reacted favourably to the news as its share price jumped more than 20% in a single day. We think IDXX’s investment thesis as a high-quality, capital-light compounder in the pet healthcare industry remains intact. That being said, IDXX is now trading at around 50x Forward P/E, and growth over the next few years is expected to be around 8%-9%. We are comfortable holding the position here, but we don’t think it is too attractive to add at the current levels. We would prefer to be patient and wait for another opportunity to add to the name.
Unlock Premium - Try 5i Free